Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 3,499 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Protein Control Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Local Antioxidant Therapy Vasoconstriction Effects in Different Races

NCT03684213
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiovascular Risk Factor, Vasoconstriction
Interventions
Control (Norepinephrine), Norepinephrine + Ascorbic Acid, Norepinephrine + L-NAME, Norepinephrine + L-NAME + Ascorbic Acid
Drug
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years to 35 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 30, 2026, 3:08 AM EDT
Completed Phase 2 Interventional

Nutritional Intervention in Children With Autism Using Whey Protein (Immunocal): Impact on Core Areas of Behavior

NCT01366859
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Whey Protein, Rice Protein (Placebo)
Dietary Supplement
Lead sponsor
Nova Southeastern University
Other
Eligibility
3 Years to 5 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 30, 2026, 3:08 AM EDT
Completed Phase 1Phase 2 Interventional

Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer

NCT01580696
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer, Fallopian Cancer, Peritoneal Cancer
Interventions
E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster, Non-vaccine clinically matched control group, E39 peptide (500mcg)/GM-CSF vaccine plus E39 booster, E39 peptide (1000mcg)/GM-CSF vaccine plus E39 booster, E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster, E39 peptide (500mcg)/GM-CSF vaccine plus J65 booster, E39 peptide (1000mcg)/GM-CSF vaccine plus J65 booster
Biological · Other
Lead sponsor
COL George Peoples, MD, FACS
Federal
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Annandale, Virginia
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Oct 30, 2026, 3:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Varying Energy Deficits on Protein Turnover at Rest and Carbohydrate Oxidation During Steady-state Exercise

NCT04910724
View directory record Official record
Conditions
Energy Supply; Deficiency, Severe, Energy Supply; Deficiency, Stress, Physiological
Interventions
Energy Deficit
Other
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 35 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 30, 2026, 3:08 AM EDT
Completed Phase 3 Interventional

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

NCT01480479
View directory record Official record
Conditions
Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component
Interventions
Rindopepimut (CDX-110) with GM-CSF, Temozolomide, KLH
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
745 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
88
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 30, 2026, 3:08 AM EDT
Completed Phase 4 Interventional

Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment

NCT01076842
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Insulin-Levemir, Exenatide-Bayetta, Insulin-Levemir and Exenatide-Bayetta, SenseWear Pro3® armband, DexCom CGM
Drug · Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 30, 2026, 3:08 AM EDT
Completed Phase 3 Interventional

Gluten Sensitivity in Non-Celiac Patients

NCT01485341
View directory record Official record
Conditions
Gluten Sensitivity
Interventions
gluten, rice starch
Dietary Supplement
Lead sponsor
University of Campania Luigi Vanvitelli
Other
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 30, 2026, 3:08 AM EDT
Completed Phase 4 Interventional Results available

Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients

NCT00693654
View directory record Official record
Conditions
Pruritis
Interventions
Sarna, Cetaphil
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 30, 2026, 3:08 AM EDT
Completed Phase 2 Interventional Results available

Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer

NCT00915603
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Everolimus, Bevacizumab, Paclitaxel, Placebo
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
15
States / cities
LaVerne, California • Norwich, Connecticut • Aventura, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Oct 30, 2026, 3:08 AM EDT
Completed Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate

NCT00673556
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
alefacept, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
16 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
10
States / cities
Irvine, California • Santa Monica, California • Omaha, Nebraska + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2014 · Synced Oct 30, 2026, 3:08 AM EDT
Completed Phase 2 Interventional

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

NCT00109161
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)
Drug
Lead sponsor
PDL BioPharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
30
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Oct 30, 2026, 3:08 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

NCT07541170
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Divarasib, Pembrolizumab, Nivolumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
6
States / cities
Clovis, California • Atlanta, Georgia • Farmington Hills, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 3:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects

NCT02594254
View directory record Official record
Conditions
Dental Caries
Interventions
C16G2 Gel, Placebo
Drug · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
10
States / cities
Imperial Beach, California • Indianapolis, Indiana • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 30, 2026, 3:08 AM EDT
Completed Phase 3 Interventional Results available

NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

NCT01098266
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
NGR-hTNF plus Best Investigator's Choice (BIC), Placebo plus Best Investigator's Choice (BIC)
Drug
Lead sponsor
AGC Biologics S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
7
States / cities
Corona, California • Duarte, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 30, 2026, 3:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome

NCT04977388
View directory record Official record
Conditions
Menkes Disease, Occipital Horn Syndrome
Interventions
Droxidopa, Placebo
Drug · Other
Lead sponsor
Stephen G. Kaler, MD
Other
Eligibility
18 Years to 50 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 30, 2026, 3:08 AM EDT
Completed Not applicable Interventional

Feeding Trial to Determine How Combinations of Different Dietary Bioactive Ingredients Influence High Density Lipoprotein (HDL) Metabolism

NCT01803594
View directory record Official record
Conditions
Dyslipidemia
Interventions
Krill Oil, Lutein, Nicotinic acid, Dairy phospholipids, Control
Dietary Supplement · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2022 · Synced Oct 30, 2026, 3:08 AM EDT
Recruiting Phase 3 Interventional

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
FOLFIRI Regimen, Sotorasib, Panitumumab, Bevacizumab-awwb
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
26
States / cities
Chandler, Arizona • Fullerton, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 30, 2026, 3:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tissue-Specific Metabolic Reprogramming in Diabetic Complications

NCT01823406
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Euglycemic clamp (normal blood sugar clamp) for 4 hours, hyperglycemic clamp (elevated blood sugar to 300) for 4 hours
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Oct 30, 2026, 3:08 AM EDT
Completed Phase 4 Interventional

A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients

NCT00240448
View directory record Official record
Conditions
Hypertension
Interventions
telmisartan 80 mg/hydrochlorothiazide 25 mg, valsartan 160 mg/hydrochlorothiazide 25 mg, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
100
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 30, 2026, 3:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Neural Substrates of Emotion: Impact of Cocaine Dependence

NCT02682784
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Oct 30, 2026, 3:08 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction

NCT02884206
View directory record Official record
Conditions
Chronic Heart Failure (CHF)
Interventions
LCZ696, Valsartan, Placebo of LCZ696, Placebo of Valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
52
States / cities
Andalusia, Alabama • Glendale, Arizona • Mesa, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 30, 2026, 3:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Insulin Receptor Substrate 1 (IRS-1) Regulation in Insulin Resistance

NCT01240252
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Human insulin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 30, 2026, 3:08 AM EDT
Completed Phase 2 Interventional Results available

Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy

NCT00737893
View directory record Official record
Conditions
Prostate Cancer, Erectile Dysfunction
Interventions
Placebo, Erythropoietin (EPO)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 65 Years · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 30, 2026, 3:08 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Collagen Protein Versus Placebo on Muscle Recovery

NCT06465407
View directory record Official record
Conditions
Anthropometrics: Height and Weight, Isometric Standing and Seated Plantarflexion, Calf Muscle Thickness, Achilles Tendon Length and Thickness, Myotonography of the Calf Musculature and Achilles Tendon, Pain Pressure Threshold of the Calf, Pain Scale, Endurance Calf Test, Dietary Analysis
Interventions
Collagen, Maltodextrin
Dietary Supplement
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 30, 2026, 3:08 AM EDT